Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 6;7(8):e07724.
doi: 10.1016/j.heliyon.2021.e07724. eCollection 2021 Aug.

Synthesis, single crystal (XRD), Hirshfeld surface analysis, computational study (DFT) and molecular docking studies of (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzenesulfonamide

N Elangovan  1 , S Sowrirajan  2
Affiliations

Synthesis, single crystal (XRD), Hirshfeld surface analysis, computational study (DFT) and molecular docking studies of (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzenesulfonamide

N Elangovan et al. Heliyon. .

Abstract

The Schiff base (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA) compound was synthesis with condensation of 3,5-diiodosalicylaldehyde and sulfadiazine. The compound characterized with FTIR, X-ray crystallography and electronic spectra. The titled compound associated with experimental and theoretical method, DFT used for the theoretical method. The IR was calculated from DFT mode with B3LYP/GENSEP basic set. The electronic spectra computed from TD-DFT method with CAM-B3LYP functional, with IEFPCM solvation model and DMSO used as the solvent. Wave function based properties like localized orbital locator, electron localization function and non-covalent interactions have been studied extensively. The ADMET properties of the compound DIDA indicated that the compound has excellent drug likeness properties and PASS studies showed that it has anti-infective properties, which is confirmed by a docking score of -7.4 kcal/mol.

Keywords: DFT; Drug-likeness; Molecular docking; Single crystal; Sulfadiazine; Synthesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Synthesis of (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 2
Figure 2
(a) ORTEP (b) optimized structure of the (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 3
Figure 3
Crystal packing diagram of (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
Figure 4
Figure 4
Hirshfeld surface map (a) dnorm, (b) di, (c) de, (d) Shape index, (e) Curvedness and (f) Fragment path of the compound (E)-4-((2-hydroxy-3,5-diiodobenzylidene)amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 5
Figure 5
Two dimensional fingerprint plot of the compound (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 6
Figure 6
Experimental and calculated FTIR spectra of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 7
Figure 7
HOMO-LUMO energy diagram of the compound (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide (DIDA).
Figure 8
Figure 8
Molecular electrostatic potential (a) color filled surface map (b) counter line map of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
Figure 9
Figure 9
Electronic spectra of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine) -2-yl) benzene sulfonamide (DIDA).
Figure 10
Figure 10
Localized orbital locator map of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
Figure 11
Figure 11
Electron localized function map of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
Figure 12
Figure 12
RDG (non-covalent interaction) map of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
Figure 13
Figure 13
Protein ligand interaction site (a) 2D diagram (b) interaction site of (E)-4-((2-hydroxy-3,5-diiodobenzylidene) amino)-N-(pyrimidine)-2-yl) benzene sulfonamide.
See this image and copyright information in PMC

References

    1. Gadad A.K., Mahajanshetti C.S., Nimbalkar S., Raichurkar A. Synthesis and an- tibacterial activity of some 5-guanylhydrazone/thiocyanato-6-arylimidazo[2,1- b ]-1,3, 4-thiadiazole-2-sulfonamide derivatives. Eur. J. Med. Chem. 2000;35:853–857. - PubMed
    1. Maren T.H. Relatons between structure and biological activity of sulfonamides. Annu. Rev. Pharmacol. Toxicol. 1976;16:309–327. - PubMed
    1. Banuppriya G., Sribalan R., Padmini V. Synthesis and characterization of cur- cumin-sulfonamide hybrids: biological evaluation and molecular docking stud- ies. J. Mol. Struct. 2018;1155:90–100.
    1. Humphries P.S., Bersot R., Kincaid J., Mabery E., McCluskie K., Park T., Ren- ner T., Riegler E., Steinfeld T., Turtle E.D., Wei Z.L., Willis E. Carbazole-containing sulfonamides and sulfamides: discovery of cryptochrome modulators as antidi- abetic agents. Bioorg. Med. Chem. Lett. 2016;26:757–760. - PubMed
    1. Sun L., Wu Y., Liu Y., Chen X., Hu L. Novel carbazole sulfonamide derivatives of antitumor agent: synthesis, antiproliferative activity and aqueous solubility. Bioorg. Med. Chem. Lett. 2017;27:261–265. - PubMed

LinkOut - more resources